173 related articles for article (PubMed ID: 30636012)
21. Pleomorphic giant cell carcinoma of the prostate: clinicopathologic analysis and oncological outcomes.
Bilé-Silva A; Lopez-Beltran A; Rasteiro H; Vau N; Blanca A; Gomez E; Gaspar F; Cheng L
Virchows Arch; 2023 Mar; 482(3):493-505. PubMed ID: 36600115
[TBL] [Abstract][Full Text] [Related]
22. High grade prostatic intraepithelial neoplasia does not display loss of heterozygosity at the mutation locus in BRCA2 mutation carriers with aggressive prostate cancer.
Willems-Jones A; Kavanagh L; Clouston D; Bolton D; ; Fox S; Thorne H
BJU Int; 2012 Dec; 110(11 Pt C):E1181-6. PubMed ID: 23035815
[TBL] [Abstract][Full Text] [Related]
23. Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer.
Ritch E; Fu SYF; Herberts C; Wang G; Warner EW; Schönlau E; Taavitsainen S; Murtha AJ; Vandekerkhove G; Beja K; Loktionova Y; Khalaf D; Fazli L; Kushnir I; Ferrario C; Hotte S; Annala M; Chi KN; Wyatt AW
Clin Cancer Res; 2020 Mar; 26(5):1114-1125. PubMed ID: 31744831
[TBL] [Abstract][Full Text] [Related]
24. DNA repair defects in prostate cancer: impact for screening, prognostication and treatment.
Warner EW; Yip SM; Chi KN; Wyatt AW
BJU Int; 2019 May; 123(5):769-776. PubMed ID: 30281887
[TBL] [Abstract][Full Text] [Related]
25. Sporadic endometrial adenocarcinoma with MMR deficiency due to biallelic MSH2 somatic mutations.
Buecher B; De Pauw A; Bazire L; Houdayer C; Fievet A; Moncoutier V; Farkhondeh F; Melaabi S; Lyonnet DS; Golmard L
Fam Cancer; 2018 Apr; 17(2):281-285. PubMed ID: 28819700
[TBL] [Abstract][Full Text] [Related]
26. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.
Nava Rodrigues D; Rescigno P; Liu D; Yuan W; Carreira S; Lambros MB; Seed G; Mateo J; Riisnaes R; Mullane S; Margolis C; Miao D; Miranda S; Dolling D; Clarke M; Bertan C; Crespo M; Boysen G; Ferreira A; Sharp A; Figueiredo I; Keliher D; Aldubayan S; Burke KP; Sumanasuriya S; Fontes MS; Bianchini D; Zafeiriou Z; Teixeira Mendes LS; Mouw K; Schweizer MT; Pritchard CC; Salipante S; Taplin ME; Beltran H; Rubin MA; Cieslik M; Robinson D; Heath E; Schultz N; Armenia J; Abida W; Scher H; Lord C; D'Andrea A; Sawyers CL; Chinnaiyan AM; Alimonti A; Nelson PS; Drake CG; Van Allen EM; de Bono JS
J Clin Invest; 2018 Oct; 128(10):4441-4453. PubMed ID: 30179225
[TBL] [Abstract][Full Text] [Related]
27. Bringing Prostate Cancer Germline Genetics into Clinical Practice.
Das S; Salami SS; Spratt DE; Kaffenberger SD; Jacobs MF; Morgan TM
J Urol; 2019 Aug; 202(2):223-230. PubMed ID: 30730411
[TBL] [Abstract][Full Text] [Related]
28. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
Criscuolo D; Morra F; Giannella R; Cerrato A; Celetti A
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242618
[TBL] [Abstract][Full Text] [Related]
29. Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer.
Nientiedt C; Budczies J; Endris V; Kirchner M; Schwab C; Jurcic C; Behnisch R; Hoveida S; Lantwin P; Kaczorowski A; Geisler C; Dieffenbacher S; Falkenbach F; Franke D; Görtz M; Heller M; Himmelsbach R; Pecqueux C; Rath M; Reimold P; Schütz V; Simunovic I; Walter E; Hofer L; Gasch C; Schönberg G; Pursche L; Hatiboglu G; Nyarangi-Dix J; Sültmann H; Zschäbitz S; Koerber SA; Jäger D; Debus J; Duensing A; Schirmacher P; Hohenfellner M; Stenzinger A; Duensing S
Urol Oncol; 2022 Jan; 40(1):8.e11-8.e18. PubMed ID: 34325986
[TBL] [Abstract][Full Text] [Related]
30. ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma.
Laforest A; Aparicio T; Zaanan A; Silva FP; Didelot A; Desbeaux A; Le Corre D; Benhaim L; Pallier K; Aust D; Pistorius S; Blons H; Svrcek M; Laurent-Puig P
Eur J Cancer; 2014 Jul; 50(10):1740-1746. PubMed ID: 24797764
[TBL] [Abstract][Full Text] [Related]
31. Strategy in clinical practice for classification of unselected colorectal tumours based on mismatch repair deficiency.
Jensen LH; Lindebjerg J; Byriel L; Kolvraa S; Crüger DG
Colorectal Dis; 2008 Jun; 10(5):490-7. PubMed ID: 17868408
[TBL] [Abstract][Full Text] [Related]
32. DNA mismatch repair deficiency in breast carcinoma: a pilot study of triple-negative and non-triple-negative tumors.
Wen YH; Brogi E; Zeng Z; Akram M; Catalano J; Paty PB; Norton L; Shia J
Am J Surg Pathol; 2012 Nov; 36(11):1700-8. PubMed ID: 22992699
[TBL] [Abstract][Full Text] [Related]
33. Pleomorphic giant cell carcinoma of prostate: Rare tumor with unique clinicopathological, immunohistochemical, and molecular features.
El-Zaatari ZM; Thomas JS; Divatia MK; Shen SS; Ayala AG; Monroig-Bosque P; Shehabeldin A; Ro JY
Ann Diagn Pathol; 2021 Jun; 52():151719. PubMed ID: 33640702
[TBL] [Abstract][Full Text] [Related]
34. Tissue identity testing of cancer by short tandem repeat polymorphism: pitfalls of interpretation in the presence of microsatellite instability.
Much M; Buza N; Hui P
Hum Pathol; 2014 Mar; 45(3):549-55. PubMed ID: 24444463
[TBL] [Abstract][Full Text] [Related]
35. Lynch syndrome-related small intestinal adenocarcinomas.
Jun SY; Lee EJ; Kim MJ; Chun SM; Bae YK; Hong SU; Choi J; Kim JM; Jang KT; Kim JY; Kim GI; Jung SJ; Yoon G; Hong SM
Oncotarget; 2017 Mar; 8(13):21483-21500. PubMed ID: 28206961
[TBL] [Abstract][Full Text] [Related]
36. Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.
Geurts-Giele WR; Leenen CH; Dubbink HJ; Meijssen IC; Post E; Sleddens HF; Kuipers EJ; Goverde A; van den Ouweland AM; van Lier MG; Steyerberg EW; van Leerdam ME; Wagner A; Dinjens WN
J Pathol; 2014 Dec; 234(4):548-59. PubMed ID: 25111426
[TBL] [Abstract][Full Text] [Related]
37. A Pilot Study of Clinical Targeted Next Generation Sequencing for Prostate Cancer: Consequences for Treatment and Genetic Counseling.
Cheng HH; Klemfuss N; Montgomery B; Higano CS; Schweizer MT; Mostaghel EA; McFerrin LG; Yu EY; Nelson PS; Pritchard CC
Prostate; 2016 Oct; 76(14):1303-11. PubMed ID: 27324988
[TBL] [Abstract][Full Text] [Related]
38. Loss of heterozygosity and microsatellite instability at chromosomal sites 1Q and 10Q in morphologically distinct regions of late stage prostate lesions.
Latini JM; Rieger-Christ KM; Wang DS; Silverman ML; Libertino JA; Summerhayes IC
J Urol; 2001 Nov; 166(5):1931-6. PubMed ID: 11586263
[TBL] [Abstract][Full Text] [Related]
39. Rhabdomyosarcoma in patients with constitutional mismatch-repair-deficiency syndrome.
Kratz CP; Holter S; Etzler J; Lauten M; Pollett A; Niemeyer CM; Gallinger S; Wimmer K
J Med Genet; 2009 Jun; 46(6):418-20. PubMed ID: 19293170
[TBL] [Abstract][Full Text] [Related]
40. DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer.
Lu E; Thomas GV; Chen Y; Wyatt AW; Lloyd P; Youngren J; Quigley D; Bergan R; Bailey S; Beer TM; Feng FY; Small EJ; Alumkal JJ
J Natl Compr Canc Netw; 2018 Aug; 16(8):933-937. PubMed ID: 30099369
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
